GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (OSL:BGBIO) » Definitions » Deferred Policy Acquisition Costs

BerGenBio ASA (OSL:BGBIO) Deferred Policy Acquisition Costs


View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


BerGenBio ASA (OSL:BGBIO) Business Description

Industry
Traded in Other Exchanges
Address
Mollendalsbakken 9, Bergen, NOR, 5009
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is d is curently being developed in STK11 mutated NSCLC and severe respiratory infections including COVID-19. .